Lorenza M. Landi
Rome, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 99 publications
Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: May 26, 2026
Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 06, 2026
Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study.
Journal: Clinical lung cancer
Published: January 11, 2026
Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 17, 2025
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: August 17, 2025
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry.
Journal: Journal for immunotherapy of cancer
Published: July 31, 2025
ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 18, 2025
Crizotinib in Patients With ROS1-Positive NSCLC With or Without Brain Metastases: Post Hoc Analysis of Phase II METROS Trial.
Journal: JTO clinical and research reports
Published: June 03, 2025
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer.
Journal: JAMA oncology
Published: May 22, 2025
First-line treatment in EGFR-mutated non-small cell lung cancer: brief report of an individual patient data comparison of phase 3 clinical trials.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 13, 2025
Spatial transcriptomics highlights B cells as key contributors to a complete and durable response to chemo-immunotherapy in a patient with resectable NSCLC.
Journal: Journal for immunotherapy of cancer
Published: May 01, 2025
BRAF mutation and neoadjuvant chemo-immunotherapy, is it worthwhile?
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 14, 2025
Last Updated: 09/26/2026